Compare · DXCM vs ICUI
DXCM vs ICUI
Side-by-side comparison of DexCom Inc. (DXCM) and ICU Medical Inc. (ICUI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and ICUI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 7.9x ICUI ($4.18B).
- DXCM has hit the wire 6 times in the past 4 weeks while ICUI has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 15 for ICUI).
- Company
- DexCom Inc.
- ICU Medical Inc.
- Price
- -
- -
- Market cap
- $33.10B
- $4.18B
- 1M return
- -
- +6.66%
- 1Y return
- -
- +37.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 1992
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 15
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
ICU Medical Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest ICUI
- VP, General Counsel Sanzone Virginia Ruth sold $819,150 worth of shares (4,856 units at $168.69) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 14,604 units (SEC Form 4)
- Chief Financial Officer Bonnell Brian Michael sold $1,116,675 worth of shares (6,381 units at $175.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 56,062 units (SEC Form 4)
- Chief Financial Officer Bonnell Brian Michael sold $1,608,143 worth of shares (9,307 units at $172.79) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 62,443 units (SEC Form 4)
- ICU Medical to Participate in Upcoming Investor Conferences
- VP, GM-Infusion Capital Woolson Daniel sold $982,265 worth of shares (5,417 units at $181.33), decreasing direct ownership by 24% to 17,062 units (SEC Form 4)
- Chief Information Officer Sousa Ben sold $401,209 worth of shares (2,250 units at $178.32), decreasing direct ownership by 42% to 3,076 units (SEC Form 4)
- Chief Operating Officer Voigtlander Christian B. sold $1,633,404 worth of shares (8,929 units at $182.93), decreasing direct ownership by 19% to 37,377 units (SEC Form 4)
- Director Finney Elisha W sold $68,978 worth of shares (378 units at $182.48), decreasing direct ownership by 7% to 4,871 units (SEC Form 4)
- SEC Form 10-Q filed by ICU Medical Inc.
- ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits